Adult patients with high-grade B-cell lymphoma undergoing treatment with CD19 chimeric antigen receptor (CAR) T-cells. Cancer
Conditions
Interventions
This multi-centre observational study has two components: (1) prospective recruitment of a cohort of patients with high grade B-cell lymphoma undergoing CD19 CAR-T therapy for sampling and longitudina
(2) retrospective data collection on patients who have previously undergone CD19 CAR-T therapy for treatment of high grade B-cell lymphoma from participating centres.
(1) Prospective cohort
A prospec
all patients will receive standard of care in the UK National Health Service (NHS).
Participants will be recruited from haematology clinics when they agree to undertake CAR-T therapy and will provide
Sponsors
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Male or female sex 2. Age 18 years or older to no upper limit 3. Has mental capacity to give informed consent 4. Has a confirmed diagnosis of high-grade B-cell lymphoma 5. Planned to undertake therapy with CAR-T cells targeting CD19 as a treatment for their lymphoma (any CD19 targeting CAR T-cell product can be included)
Exclusion criteria
Exclusion criteria: 1. Age below 18 years 2. Not able to provide informed consent eg lacks capacity 3. Patient is a prisoner 4. Patient is pregnant 5. Previous receipt of an allogeneic bone marrow transplant (allo-HSCT) 6. A history of recurrent or serious nosebleeds, or nasal polyps, or any other abnormalities or on-going medical conditions affecting the nose that would contra-indicate taking nasal swabs 7. Having undergone nasal surgery in the last year 8. Having had a broken nose in the last year 9. Any defects of the skull base or hard palate
Countries
England, United Kingdom
Contacts
Public ContactWilliam Hamilton
Outcome results
None listed